A BuiltForAI Property
Live data · NADAC + Part D CY24 · reviewed daily

Ambrisentan (Letairis)

Endothelin Receptor Antagonist class · 8 generic manufacturers · 16 ANDAs filed at FDA.

First FDA approval2007-06-15
Generic availableYes · 8 mfrs
Shortage statusNone
340B exposureunknown
Last updated
NADAC: weekly (every Wed)Part D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily
At a glance · the numbers a plan sponsor wants on screen one

$364.6M in CY2024 Part D spend98K claims · 15K beneficiaries · 329 plans surveyed

Lowest NADAC
$8.34/unit
9 NDCs benchmarked, lowest of all strengths.
Average NADAC
$8.34
Across all dosage forms in distribution.
Highest NADAC
$8.34
Range is tight.
Plans with PA
562 / 329
Substantial PA friction across plans.

Questions a plan sponsor actually asks.

FAQPage schema11 entries indexed · 4 visible
What is Ambrisentan used for?

Ambrisentan is a Endothelin Receptor Antagonist medication tracked in Medicare Part D.

Is there a generic for Ambrisentan?

Yes. 16 ANDAs filed at FDA, 8 generic manufacturers currently shipping.

How much does my plan pay for Ambrisentan?

Across 329 Part D plans, Ambrisentan averages $8.34/unit (NADAC). Lowest available: $8.34/unit. Highest in distribution: $8.34/unit.

Is Ambrisentan on the FDA shortage list?

No. Ambrisentan is not currently on the FDA Drug Shortage Database.

7 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.

Same class. Different math.

Endothelin Receptor Antagonist5 alternatives in D1
01
Aprocitentan
Brand: TRYVIO
Lowest NADAC
0Generic mfrs
$77,158CY24 Part D spend
Compare →
02
Bosentan
Brand: Tracleer
Lowest NADAC
4Generic mfrs
$48.1MCY24 Part D spend
Compare →
03
Macitentan
Brand: OPSUMIT
Lowest NADAC
5Generic mfrs
$1.87BCY24 Part D spend
Compare →
04
Macitentan and Tadalafil
Brand: OPSYNVI
Lowest NADAC
0Generic mfrs
CY24 Part D spend
Compare →
05
Sparsentan
Brand: FILSPARI
Lowest NADAC
0Generic mfrs
$48.4MCY24 Part D spend
Compare →

Sources · every number above traces back.

Last refresh30 May 2026

Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (10 approvals on file) · NADAC unit costs: CMS NADAC weekly file (9 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.